RS
NMRA icon

R Squared’s Neumora Therapeutics NMRA Stock Holding History

R Squared’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.2K Buy
+16,596
New +$31.6K 0.01% 475
2025
Q4 		– Sell
-13,381
Closed -$24.4K – 652
2025
Q3 		$24.4K Sell
13,381
-11,682
-47% -$18.9K 0.01% 523
2025
Q2 		$18.4K Buy
+25,063
New +$19K 0.01% 445
2025
Q1 		– Sell
-1,210
Closed -$12.8K – 1068
2024
Q4 		$12.8K Buy
+1,210
New +$14.5K 0.01% 1068

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

R Squared's NMRA Position: Q2 2026 in Review

R Squared opened a new position in Neumora Therapeutics (NMRA) in Q2 2026: 16,596 shares worth $28.2K. The stake represents 0.01% of the portfolio and ranks #475 among its holdings. This is a return to the name: R Squared previously reported a position in NMRA as recently as Q3 2025.

R Squared first reported a position in NMRA in Q4 2024 and has held it in 4 quarters since. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • R Squared held 16,596 shares of Neumora Therapeutics worth $28.2K as of Q2 2026.
  • Neumora Therapeutics was a new R Squared position in Q2 2026.
  • Neumora Therapeutics made up 0.01% of R Squared's portfolio in Q2 2026, its #475 holding.
  • R Squared first reported a position in Neumora Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on R Squared's 13F filing for Q2 2026, filed 5 Aug 2026.